Techulon Teams with BioConcept for European

BLACKSBURG, Va.–Techulon Inc., the leader in low-toxicity gene delivery has signed a distribution agreement with BioConcept of Allschwil, Switzerland. Glycofect is a polymeric nanoparticle-delivery transfection reagent designed to be particularly effective in primary cells of therapeutic interest. It is being used in over 20 countries by government, university and corporate laboratories for advanced research towards better understanding of cell biology and for development of new cell-based therapeutics.

“BioConcept, leading manufacturer of Swiss made cell culture media (AMIMED®), is proud to be the partner of Techulon for distribution of Glycofect,” said Martin Howald, CEO/President of BioConcept. “The innovative nature of Glycofect perfectly fits BioConcept’s portfolio and the combination of Glycofect with MAM-PF – our chemically defined, protein-, serum- and animal component free CHO production medium, will give our valued customers additional benefits.”

“We are very pleased to have BioConcept represent Techulon. Swiss and European institutions are leaders in cell-based therapeutics research, and as research focus shifts towards primary cells we expect to see strong growth with our Glycofect reagents,” said Frank Akers, President of Techulon. “We believe that BioConcept has an excellent product portfolio and customer base that will expand our market penetration throughout Europe.”

About Techulon

Techulon, Inc. is a life sciences company headquartered in Blacksburg, VA, with a core capability in novel biodegradable and low toxicity DNA and RNA delivery reagents for cell-based research and therapeutics. For more information please visit the company website at www.techulon.com.

About BioConcept

BioConcept is a dedicated ‘system supplier’ to the Swiss biological research community since more than 30 years, supporting its customers with a comprehensive and high-tech product portfolio, supplying reagents, disposables, laboratory equipment and instrumentation for applications in the fields of cell biology, molecular biology and immunology. AMIMED® is the registered trademark of BioConcepts cell and tissue culture product line manufactured in Switzerland with focus on Animal Component Free media manufactured according to GMP guidelines. For more information visit the BioConcept website at www.bioconcept.ch

< | >